We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Colchicineis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Colchicine studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2013–2025 with a typical study size of 5,522 participants.
Based on 6 studies · 1 meta-analysis · 4 RCTs · 6,054 total participants
Confidence
ModerateBy outcome
Colchicine has an evidence score of 3/10 — emerging evidence based on 6 indexed studies, including 1 meta-analysis. An ancient anti-inflammatory drug (from autumn crocus) for gout and familial Mediterranean fever, now studied as a geroprotector targeting 'inflammaging.' Randomized trials (LoDoCo2, COLCOT) show low-dose colchicine reduces cardiovascular events in coronary disease — proof that dampening chronic inflammation has real outcome benefit. Lifespan itself is unproven. A prescription drug used off-label, not a supplement. Representative study: PMID 35033433.
The commonly studied dose of Colchicine is Off-label cardiovascular/geroprotective use is low-dose: 0.5 mg once daily (the LoDoCo2 regimen) under a clinician. Acute gout uses higher short-course dosing. Not an approved longevity regimen; mind the drug interactions.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
MitoQ
Mostly mechanism / observationalLast reviewed June 2026 · evidence from 6 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Colchicine (anti-inflammatory)
An ancient anti-inflammatory drug (from autumn crocus) for gout and familial Mediterranean fever, now studied as a geroprotector targeting 'inflammaging.' Randomized trials (LoDoCo2, COLCOT) show low-dose colchicine reduces cardiovascular events in coronary disease — proof that dampening chronic inflammation has real outcome benefit. Lifespan itself is unproven. A prescription drug used off-label, not a supplement.
Colchicine is the best RCT-backed test of targeting 'inflammaging' — low-dose colchicine reduced cardiovascular events in LoDoCo2/COLCOT — but the large CLEAR-SYNERGY (OASIS-9) trial found NO benefit after acute MI, so the cardiovascular case is now genuinely contested; there is no lifespan/healthspan trial, and it has a narrow margin with serious interactions.
Colchicine is one of the oldest drugs in continuous use — an alkaloid from the autumn crocus, long used for acute gout and familial Mediterranean fever. It works by binding tubulin and disrupting microtubules, which impairs neutrophil function and inhibits the NLRP3 inflammasome, broadly dampening innate inflammation.
Its geroscience relevance is the concept of 'inflammaging': chronic, low-grade inflammation (driven partly by the NLRP3 inflammasome and senescent-cell secretions) is a hallmark of aging that drives cardiovascular disease, frailty, and neurodegeneration.
Colchicine is the best-evidenced test of whether pharmacologically lowering this inflammation improves hard outcomes — and the answer, at least for the heart, is yes: the randomized LoDoCo and LoDoCo2 trials showed low-dose colchicine (0.5 mg/day) reduced major cardiovascular events in patients with stable coronary disease, and COLCOT showed benefit after myocardial infarction, with meta-analyses confirming the cardiovascular reduction.
This is a genuine, RCT-backed demonstration that targeting inflammaging changes outcomes.
The honest limits: those trials are cardiovascular, not longevity — there is no trial showing colchicine extends lifespan or healthspan broadly; some analyses note more non-cardiovascular deaths/infections, so the net is debated; and colchicine has a narrow therapeutic margin with significant GI side effects (diarrhea), dangerous drug interactions (it is a CYP3A4/P-gp substrate — combining with clarithromycin, certain statins, or grapefruit can cause toxicity), and serious toxicity in overdose.
Colchicine is a prescription drug used off-label for its anti-inflammatory/geroprotective effects; it is not a dietary supplement.
The score reflects real RCT evidence that lowering inflammaging reduces cardiovascular events, against the absence of a longevity trial, a debated net mortality balance, and meaningful toxicity/interactions.
Colchicine binds tubulin and disrupts microtubules, impairing neutrophil chemotaxis and activation — the basis of its anti-inflammatory effect.
It inhibits the NLRP3 inflammasome, lowering IL-1β/IL-6 signaling central to 'inflammaging' and atherosclerosis.
By dampening chronic low-grade inflammation — a hallmark of aging — it addresses a driver of cardiovascular disease, frailty, and neurodegeneration.
How Colchicine works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Off-label cardiovascular/geroprotective use is low-dose: 0.5 mg once daily (the LoDoCo2 regimen) under a clinician. Acute gout uses higher short-course dosing. Not an approved longevity regimen; mind the drug interactions.
Take with food
| Form | Type |
|---|---|
| 💊Low-dose oral tablet (0.5 mg/day) | Recommended |
The cardiovascular evidence (LoDoCo2/COLCOT) used low daily dosing, not the higher gout dose.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Low daily dose with food; avoid grapefruit and CYP3A4/P-gp inhibitors. Dose-reduce in renal/hepatic impairment.
Dose-response data unavailable. The current published research for Colchicine does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Low-dose colchicine reduced major cardiovascular events in coronary disease and after MI in randomized trials.
Reduces CRP and inflammasome-driven signaling — a direct test of the inflammaging hypothesis.
Some trials/analyses noted more non-cardiovascular deaths or infections, so the overall mortality balance is debated.
Diarrhea is common; it has a narrow margin and dangerous CYP3A4/P-gp interactions (e.g. clarithromycin, some statins, grapefruit).
Avoid or dose-reduce sharply — dangerous CYP3A4/P-gp interaction.
Dose-reduce and monitor — higher toxicity risk.
Used in FMF under specialist care; not for off-label longevity use in pregnancy.
Markedly raise colchicine levels — can cause life-threatening toxicity. A critical interaction.
Additive myopathy/rhabdomyolysis risk with some statins.
Tip: Most common dose-limiting effect; take with food, reduce dose.
Tip: More likely with renal impairment or interacting drugs; monitor for muscle weakness.
Tip: Narrow margin; overdose is a medical emergency — strict dosing and interaction checks.
Timing is flexible for Colchicine — consistent daily use matters more than the time of day. Low once-daily dosing for cardiovascular/anti-inflammatory use; take with food to limit GI upset.
Colchicine should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are diarrhea / GI upset, myopathy / neuromyopathy, bone-marrow suppression / severe toxicity (overdose). Use caution if any of these apply to you: Significant renal or hepatic impairment (with interacting drugs); Concurrent strong CYP3A4/P-gp inhibitors; Pregnancy (relative; specialist-directed in FMF).
A mitochondria-targeted antioxidant — CoQ10 conjugated to a triphenylphosphonium (TPP+) cation so it accumulates several-hundred-fold inside mitochondria. Sold OTC as a supplement. Its best human signal is improved endothelial/vascular function in older adults (one small RCT); several trials are null (Parkinson's, exercise adaptation), and almost all outcomes are surrogate/biomarker, not hard clinical endpoints.